The Harvard Bioscience, Inc. (HBIO) Shares Bought by Essex Investment Management Co. LLC

The Harvard Bioscience, Inc. (HBIO) Shares Bought by Essex Investment Management Co. LLC

Several other large investors also recently bought and sold shares of HBIO. Algert Global LLC boosted its stake in Harvard Bioscience by 17.7% in the first quarter. Algert Global LLC now owns 113,818 shares of the medical instruments supplier’s stock valued at $296,000 after buying an additional 17,120 shares in the last quarter. Spark Investment Management LLC boosted its stake in Harvard Bioscience by 12.8% in the first quarter. Spark Investment Management LLC now owns 116,950 shares of the medical instruments supplier’s stock valued at $304,000 after buying an additional 13,250 shares in the last quarter. Renaissance Technologies LLC boosted its stake in Harvard Bioscience by 5.9% in the first quarter. Renaissance Technologies LLC now owns 560,500 shares of the medical instruments supplier’s stock valued at $1,457,000 after buying an additional 31,300 shares in the last quarter. Foundry Partners LLC boosted its stake in Harvard Bioscience by 6.2% in the first quarter. Foundry Partners LLC now owns 666,200 shares of the medical instruments supplier’s stock valued at $1,732,000 after buying an additional 38,750 shares in the last quarter. Finally, Royce & Associates LP boosted its stake in Harvard Bioscience by 2.9% in the first quarter. Royce & Associates LP now owns 1,557,600 shares of the medical instruments supplier’s stock valued at $4,050,000 after buying an additional 44,000 shares in the last quarter. 61.94% of the stock is owned by hedge funds and other institutional investors.

Essex Investment Management Co. LLC increased its stake in Harvard Bioscience, Inc. (NASDAQ:HBIO) by 38.7% during the second quarter, Holdings Channel reports. The institutional investor owned 429,460 shares of the medical instruments supplier’s stock after buying an additional 119,878 shares during the period. Essex Investment Management Co. LLC’s holdings in Harvard Bioscience were worth $1,095,000 as of its most recent filing with the SEC.

Shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) opened at 2.95 on Wednesday. The stock has a 50 day moving average of $2.58 and a 200 day moving average of $2.65. The stock’s market capitalization is $102.12 million. Harvard Bioscience, Inc. has a 52-week low of $2.25 and a 52-week high of $3.30.

Harvard Bioscience (NASDAQ:HBIO) last posted its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $0.01 EPS for the quarter, missing the Zacks’ consensus estimate of $0.03 by $0.02. The company had revenue of $25.21 million during the quarter, compared to the consensus estimate of $24 million. Harvard Bioscience had a positive return on equity of 1.46% and a negative net margin of 4.37%. Analysts forecast that Harvard Bioscience, Inc. will post $0.15 earnings per share for the current year.

Several equities research analysts have recently commented on HBIO shares. Zacks Investment Research raised shares of Harvard Bioscience from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research report on Wednesday, July 12th. TheStreet raised shares of Harvard Bioscience from a “d+” rating to a “c-” rating in a research report on Monday. Finally, ValuEngine raised shares of Harvard Bioscience from a “sell” rating to a “hold” rating in a research report on Tuesday. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Harvard Bioscience has a consensus rating of “Buy” and a consensus target price of $4.75.

In related news, Director Earl R. Lewis purchased 12,238 shares of the business’s stock in a transaction dated Thursday, May 25th. The shares were purchased at an average cost of $2.35 per share, for a total transaction of $28,759.30. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jeffrey Duchemin purchased 22,000 shares of the business’s stock in a transaction dated Monday, June 12th. The stock was bought at an average price of $2.76 per share, for a total transaction of $60,720.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders bought 52,950 shares of company stock worth $135,275. Company insiders own 8.80% of the company’s stock.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors.

Want to see what other hedge funds are holding HBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Harvard Bioscience, Inc. (NASDAQ:HBIO).

Related posts

Leave a Comment